[pubmed] Significance of anti-striational antibodies for immune checkpoint inhibitor-related myositis: a comment on the

[RSS-Bot]

Arthritis Rheumatol. 2021 Mar 7. doi: 10.1002/art.41713. Online ahead of print.

ABSTRACT

Aldrich et al. clearly described the clinical features of immune checkpoint inhibitor-related myositis (ICI-myositis) divided by the presence or absence of myasthenia gravis (MG) (1). From the viewpoint of a neurologist, I emphasize that making a diagnosis of MG that has occurred as immune-related adverse event is difficult when anti-acetylcholine receptor (AChR) antibodies are undetectable.

PMID:33682362 | DOI:10.1002/art.41713


Source: https://pubmed.ncbi.nlm.nih.gov/3368236 ... 8&v=2.14.2